Abstract
Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic NETs are a subset of NET that arise from the gastrointestinal tract. The natural history and prognosis varies widely between different gastroenteropancreatic NETs, highlighting the importance of identifying accurate prognostic and predictive biomarkers. At the 2013 ASCO Gastrointestinal Cancers Symposium, De Braud et al. (Abstract #186) and Bellister et al. (Abstract #163) present data on two new possible biomarkers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 155-157 |
| Number of pages | 3 |
| Journal | Journal of the Pancreas |
| Volume | 14 |
| Issue number | 2 |
| State | Published - Mar 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Biological markers
- Gastro-enteropancreatic neuroendocrine tumors
- Human
- PHLPP2 protein
- Succinate dehydrogenase
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology
Fingerprint
Dive into the research topics of 'Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors: Highlights from the "2013 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. january 24-26, 2013'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS